Patisiran
Phase 3Completed 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Amyloidosis, Familial
Conditions
Amyloidosis, Familial, Transthyretin Amyloidosis
Trial Timeline
Mar 27, 2019 → Oct 20, 2020
NCT ID
NCT03862807About Patisiran
Patisiran is a phase 3 stage product being developed by Alnylam Pharmaceuticals for Amyloidosis, Familial. The current trial status is completed. This product is registered under clinical trial identifier NCT03862807. Target conditions include Amyloidosis, Familial, Transthyretin Amyloidosis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05505838 | Pre-clinical | Completed |
| NCT05023889 | Phase 1 | Active |
| NCT04201418 | Pre-clinical | Completed |
| NCT03862807 | Phase 3 | Completed |
| NCT02510261 | Phase 3 | Completed |
| NCT01617967 | Phase 2 | Completed |
Competing Products
20 competing products in Amyloidosis, Familial